

Justin Musinsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3439327/publications.pdf>

Version: 2024-02-01

186
papers

19,423
citations

15495

65
h-index

13365

130
g-index

194
all docs

194
docs citations

194
times ranked

23638
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation. New England Journal of Medicine, 2002, 346, 1609-1615.	13.9	1,363
2	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
3	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
4	Integrative clinical genomics of metastatic cancer. Nature, 2017, 548, 297-303.	13.7	685
5	Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genetics, 1997, 17, 79-83.	9.4	630
6	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337.	0.8	522
7	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
8	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428
9	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	0.8	397
10	Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
11	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	9.4	377
12	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
13	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	3.8	366
14	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
15	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	2.3	314
16	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	13.7	295
17	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
18	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	286

#	ARTICLE	IF	CITATIONS
19	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. <i>Nature Genetics</i> , 1996, 13, 126-128.	9.4	282
20	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 1226-1231.	9.4	270
21	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. <i>JAMA Oncology</i> , 2016, 2, 104.	3.4	270
22	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020, 38, 674-685.	0.8	270
23	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
24	Germline <i>BRCA</i> Mutations Denote a Clinicopathologic Subset of Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2115-2121.	3.2	263
25	Counselling framework for moderate-penetrance cancer-susceptibility mutations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 581-588.	12.5	258
26	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
27	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	242
28	The "Duty to Warn" a Patient's Family Members About Hereditary Disease Risks. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1469.	3.8	228
29	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
30	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
31	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. <i>Nature Communications</i> , 2020, 11, 597.	5.8	193
32	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. <i>JAMA Oncology</i> , 2016, 2, 1434.	3.4	189
33	Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1548-1551.	3.0	183
34	Personalized medicine: new genomics, old lessons. <i>Human Genetics</i> , 2011, 130, 3-14.	1.8	173
35	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015, 121, 4382-4388.	2.0	167
36	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. <i>Nature Communications</i> , 2014, 5, 4835.	5.8	156

#	ARTICLE	IF	CITATIONS
37	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	1.5	148
38	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	9.4	147
39	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228.	3.4	132
40	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	3.0	129
41	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. PLoS Genetics, 2015, 11, e1005262.	1.5	128
42	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
43	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. American Journal of Human Genetics, 2020, 107, 432-444.	2.6	124
44	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
45	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American Journal of Human Genetics, 2016, 98, 801-817.	2.6	113
46	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Medical Genomics, 2017, 10, 33.	0.7	111
47	Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	0.6	110
48	Leukemic differentiation of a mediastinal germ cell tumor. Genes Chromosomes and Cancer, 1989, 1, 83-87.	1.5	109
49	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	2.3	108
50	Cancer Genetic Testing and Assisted Reproduction. Journal of Clinical Oncology, 2006, 24, 4775-4782.	0.8	107
51	Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Medical Genetics, 2003, 4, 1.	2.1	106
52	Genomic Profiles for Disease Risk. JAMA - Journal of the American Medical Association, 2008, 299, 1353.	3.8	100
53	18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. British Journal of Haematology, 1989, 72, 178-183.	1.2	97
54	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	2.6	96

#	ARTICLE	IF	CITATIONS
55	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	5.8	94
56	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
57	<i>FANCM</i>c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	1.4	91
58	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
59	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. <i>Gastroenterology</i> , 2020, 158, 1300-1312.e20.	0.6	90
60	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88
61	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
62	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	0.8	83
63	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
64	Clonal hematopoiesis is associated with risk of severe Covid-19. <i>Nature Communications</i> , 2021, 12, 5975.	5.8	81
65	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
66	Preimplantation Genetic Diagnosis for Cancer Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2727.	3.8	77
67	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. <i>BMC Medicine</i> , 2020, 18, 396.	2.3	76
68	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
69	Susceptibility Loci Associated with Prostate Cancer Progression and Mortality. <i>Clinical Cancer Research</i> , 2010, 16, 2819-2832.	3.2	74
70	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021, 2, 357-365.	5.7	74
71	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	3.0	66
72	Gene Patents and Personalized Cancer Care: Impact of the <i>Myriad</i> Case on Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 2743-2748.	0.8	60

#	ARTICLE	IF	CITATIONS
73	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. <i>Journal of Clinical Oncology</i> , 2020, 38, 1398-1408.	0.8	60
74	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	5.8	58
75	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
76	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
77	Involvement of <i>BCL6</i> in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. <i>Journal of Clinical Investigation</i> , 1998, 23, 323-327.		47
78	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
79	Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. <i>Human Genetics</i> , 2019, 138, 307-326.	1.8	44
80	Genetic architectures of proximal and distal colorectal cancer are partly distinct. <i>Gut</i> , 2021, 70, 1325-1334.	6.1	44
81	Twenty-one gene recurrence score assay in <i>BRCA</i> associated versus sporadic breast cancers: Differences based on germline mutation status. <i>Cancer</i> , 2016, 122, 1178-1184.	2.0	42
82	Inheritance of deleterious mutations at both <i>BRCA1</i> and <i>BRCA2</i> in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
83	Genomic Biomarkers for Breast Cancer Risk. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 1-32.	0.8	42
84	A Recurrent <i>ERCC3</i> Truncating Mutation Confers Moderate Risk for Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 1267-1275.	7.7	41
85	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2015, 24, 3595-3607.	1.4	40
86	Inherited <i>TP53</i> Variants and Risk of Prostate Cancer. <i>European Urology</i> , 2022, 81, 243-250.	0.9	40
87	Clonal cytogenetic abnormalities in Hodgkin's disease. <i>Genes Chromosomes and Cancer</i> , 1991, 3, 294-299.	1.5	36
88	Variants at <i>IRX4</i> as prostate cancer expression quantitative trait loci. <i>European Journal of Human Genetics</i> , 2014, 22, 558-563.	1.4	36
89	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> , 2021, 160, 1164-1178.e6.	0.6	36
90	Assessing Associations between the <i>AURKA-HMMR-TPX2-TUBG1</i> Functional Module and Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34

#	ARTICLE	IF	CITATIONS
91	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. <i>JCO Oncology Practice</i> , 2022, 18, 201-209.	1.4	34
92	Germline <i>SDHA</i> mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002584.	0.5	33
93	A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. <i>Cancer Research</i> , 2020, 80, 3732-3744.	0.4	32
94	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
95	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
96	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. <i>Genetics in Medicine</i> , 2018, 20, 1324-1327.	1.1	31
97	Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , 2020, 11, 2220.	5.8	31
98	<i>BCL6</i> Gene Rearrangement and Other Cytogenetic Abnormalities in Diffuse Large Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1995, 20, 85-89.	0.6	30
99	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i>BRCA2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
100	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. <i>PLoS Genetics</i> , 2018, 14, e1007111.	1.5	30
101	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. <i>Genetics in Medicine</i> , 2021, 23, 2105-2113.	1.1	29
102	Rare variants of <i>ATM</i> and risk for Hodgkin's disease and radiation-associated breast cancers. <i>Clinical Cancer Research</i> , 2002, 8, 3813-9.	3.2	29
103	Ethical and Legal Aspects of Cancer Genetic Testing. <i>Seminars in Oncology</i> , 2007, 34, 435-443.	0.8	28
104	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019, 43, 844-863.	0.6	28
105	Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. <i>BMC Medicine</i> , 2020, 18, 229.	2.3	28
106	Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. <i>Journal of Oncology Practice</i> , 2017, 13, e590-e601.	2.5	27
107	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1490-1502.	2.2	27
108	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26

#	ARTICLE	IF	CITATIONS
109	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. <i>European Journal of Human Genetics</i> , 2017, 25, 432-438.	1.4	26
110	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. <i>Human Mutation</i> , 2019, 40, 1781-1796.	1.1	26
111	Mendelian Randomization of Circulating Polyunsaturated Fatty Acids and Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 860-870.	1.1	26
112	Fumarate hydratase <i>FH</i> c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. <i>Human Mutation</i> , 2020, 41, 103-109.	1.1	25
113	Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 477-486.	1.1	25
114	High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. <i>Human Genetics</i> , 2018, 137, 343-355.	1.8	24
115	Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1871-1879.	0.5	24
116	The future of clinical cancer genomics. <i>Seminars in Oncology</i> , 2016, 43, 615-622.	0.8	23
117	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. <i>Cancer</i> , 2020, 126, 3114-3121.	2.0	23
118	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1429-1437.	3.2	23
119	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
120	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
121	Chromosome Analysis in the Management of Patients with Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1992, 7, 275-282.	0.6	21
122	Germline deletion of <i>ETV6</i> in familial acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1039-1046.	2.5	21
123	Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. <i>Neuron</i> , 2021, 109, 1465-1478.e4.	3.8	21
124	Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 238.e1-238.e7.	0.8	20
125	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
126	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19

#	ARTICLE	IF	CITATIONS
127	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
128	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
129	A decade of discovery in cancer genomics. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 632-634.	12.5	17
130	Germline BRCA2 mutations detected in pediatric sequencing studies impact parents' evaluation and care. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001925.	0.5	17
131	Development of Clinical Domain Working Groups for the Clinical Genome Resource (ClinGen): lessons learned and plans for the future. <i>Genetics in Medicine</i> , 2019, 21, 987-993.	1.1	17
132	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 447-456.	1.1	16
133	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 297-306.	1.1	16
134	Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. <i>British Journal of Cancer</i> , 2018, 118, 1639-1647.	2.9	16
135	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
136	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	2.6	16
137	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	1.1	15
138	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182.	5.8	15
139	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1997-2010.	3.2	15
140	Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1336-1348.	1.1	15
141	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114753.	2.8	15
142	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	2.2	15
143	Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. <i>Journal of Genetic Counseling</i> , 2017, 26, 232-243.	0.9	14
144	A case for expert curation: an overview of cancer curation in the Clinical Genome Resource (ClinGen). <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004739.	0.5	14

#	ARTICLE	IF	CITATIONS
145	A family with three germline mutations in <i>BRCA1</i> and <i>BRCA2</i> . <i>Clinical Genetics</i> , 1998, 54, 215-218.	1.0	13
146	Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. <i>Cancer</i> , 2017, 123, 2452-2458.	2.0	12
147	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	1.1	10
148	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e031092.	0.8	10
149	Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient Population. <i>JCO Precision Oncology</i> , 2021, 5, 455-465.	1.5	10
150	Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1508-1508.	0.8	10
151	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459.	1.1	10
152	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. <i>JCO Precision Oncology</i> , 2020, 4, 916-925.	1.5	9
153	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	2.9	9
154	Germline <i>RAD51B</i> variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. <i>Npj Breast Cancer</i> , 2021, 7, 135.	2.3	9
155	Ethicolegal Aspects of Cancer Genetics. <i>Cancer Treatment and Research</i> , 2010, 155, 1-14.	0.2	8
156	Factors Influencing Patient Preferences for Telehealth Cancer Genetic Counseling During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2022, 18, e462-e471.	1.4	8
157	Multigene Testing for Hereditary Cancer: When, Why, and How. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 741-743.	2.3	7
158	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	7
159	Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel <i>BRCA1/2</i> Genetic Risk Modifier Test. <i>Public Health Genomics</i> , 2020, 23, 6-19.	0.6	7
160	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 362-371.	1.1	7
161	Early age of onset and broad cancer spectrum persist in <i>MSH6</i> - and <i>PMS2</i> -associated Lynch syndrome. <i>Genetics in Medicine</i> , 2022, 24, 1187-1195.	1.1	7
162	Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	6

#	ARTICLE	IF	CITATIONS
163	Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i> . <i>Cancer Prevention Research</i> , 2019, 12, 599-608.	0.7	6
164	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	1.3	6
165	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	2.6	6
166	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	6
167	Facilitated cascade testing (FaCT): a randomized controlled trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 779-783.	1.2	6
168	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
169	Response to Li and Hopper. <i>American Journal of Human Genetics</i> , 2021, 108, 527-529.	2.6	5
170	Tissue-Specific Enrichment of Lymphoma Risk Loci in Regulatory Elements. <i>PLoS ONE</i> , 2015, 10, e0139360.	1.1	5
171	Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes. <i>European Journal of Human Genetics</i> , 2019, 27, 824-828.	1.4	4
172	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4267-4277.	3.2	4
173	<i>BRCA1</i> : A new marker in the management of patients with breast cancer?. , 1996, 77, 599-601.		2
174	Germline <i>HOXB13</i> mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	1.6	2
175	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. <i>Human Molecular Genetics</i> , 2021, 30, 1142-1153.	1.4	2
176	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1504-1504.	0.8	2
177	A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. <i>PLoS ONE</i> , 2016, 11, e0146435.	1.1	2
178	Genome-wide association studies of cancer predisposition. , 2013, , 10-20.		1
179	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1262-1263.	0.8	1
180	<i>CHEK2</i> Alleles Predispose to Renal Cancer in Poland-In Reply. <i>JAMA Oncology</i> , 2019, 5, 576.	3.4	1

#	ARTICLE	IF	CITATIONS
181	Characterization of a germline splice site variant MLH1 c.678-3T>A in a Lynch syndrome family. <i>Familial Cancer</i> , 2020, 19, 315-322.	0.9	1
182	Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. <i>Genes Chromosomes and Cancer</i> , 1998, 23, 323-327.	1.5	1
183	SNPs at SMG7 associated with time from biochemical recurrence to prostate cancer death. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	1.1	1
184	Genitourinary Cancers Other than Prostate Cancer in a BRCA -tested Cohort from a Single Institution. <i>European Urology</i> , 2015, 67, 1196-1197.	0.9	0
185	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
186	Breast cancer risk prediction using the novel germ-line signatures in epigenome regulatory pathways.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1500-1500.	0.8	0